Trinity Biotech
TRIB
34 hedge funds and large institutions have $20.2M invested in Trinity Biotech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.07% less ownership
Funds ownership: 62.61% → 56.54% (-6.1%)
8% less funds holding
Funds holding: 37 → 34 (-3)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
58% less capital inflows, than outflows
Capital inflows: $2.68M | Capital outflows: $6.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$1.55M |
| 2 |
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$846K |
| 3 |
Renaissance Technologies
New York
|
+$171K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$56.4K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
22NW LP
Seattle,
Washington
|
-$2.72M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.3M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$1.29M |
| 4 |
First Wilshire Securities Management
Pasadena,
California
|
-$445K |
| 5 |
Teton Advisors
Rye,
New York
|
-$371K |
TRIB Hedge Fund Activity: Q2 2019 in Review
34 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2019, worth a combined $20.2M — down 46% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TRIB and 3 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Stonehill Capital Management, adding an estimated $1.55M. The largest seller was 22NW LP, exiting entirely with an estimated $2.72M sold.
- 34 institutional investors held Trinity Biotech (TRIB) as of Q2 2019, down from 37 in Q1 2019.
- Funds reported $20.2M of Trinity Biotech stock for Q2 2019, down 46% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2019 and 6 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q2 2019 was Stonehill Capital Management, an estimated $1.55M added.
- The largest Trinity Biotech seller in Q2 2019 was 22NW LP, an estimated $2.72M sold.
Based on aggregated 13F filings for Q2 2019.